Trials / Conditions / Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia (CML)

17 registered clinical trials studyying Chronic Myelogenous Leukemia (CML) — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Cord Blood Transplant in Adults With Blood Cancers NCT05884333	Memorial Sloan Kettering Cancer Center	Phase 2
Completed	TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution NCT03959241	Medical College of Wisconsin	Phase 3
Completed	Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and M NCT02730299	Gamida Cell ltd	Phase 3
Terminated	Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation NCT02259348	St. Jude Children's Research Hospital	Phase 2
Completed	Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation NCT02226861	National Heart, Lung, and Blood Institute (NHLBI)	Phase 1
Terminated	A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re NCT02200380	Celldex Therapeutics	Phase 2
Terminated	Phase I Study of Milatuzumab for Graft Versus Host Disease NCT01663766	Gilead Sciences	Phase 1
Completed	IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897	Masonic Cancer Center, University of Minnesota	Phase 1 / Phase 2
Completed	Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study NCT01735955	Novartis Pharmaceuticals	Phase 4
Completed	Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders NCT01758042	Massachusetts General Hospital	N/A
Completed	Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malig NCT01413568	Polyphor Ltd.	Phase 1 / Phase 2
Recruiting	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) NCT01351545	Center for International Blood and Marrow Transplant Research	—
Completed	Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation NCT01243489	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH	Phase 4
Terminated	Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells NCT01050764	Everett Meyer	Phase 1 / Phase 2
Completed	Unrelated Umbilical Cord Blood (UBC)Transplantation NCT01768845	West Virginia University	N/A
Terminated	A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation NCT00672152	Michael Morse, MD	Phase 1
No Longer Available	Nilotinib, for Patients With CML-CP or CML-AP NCT04518644	Novartis Pharmaceuticals	—